Moomoo AI 已提取核心信息
Clearmind Medicine Inc., a foreign private issuer, has filed a Report on Form 6-K with the United States Securities and Exchange Commission for February 2024, confirming its compliance with the shareholders' equity requirement for continued listing on the Nasdaq Capital Market. The company had previously reported shareholders' equity below the $2.5 million threshold as of October 31, 2023. However, Clearmind Medicine has since increased its shareholders' equity to approximately $7 million, following the exercise of warrants from its March and September 2023 public offerings and a registered direct offering and private placement in January 2024. The company believes it has regained compliance with the Nasdaq's listing requirements and understands that Nasdaq will monitor its ongoing compliance, with potential delisting if non-compliance is found in the next interim report.
Clearmind Medicine Inc., a foreign private issuer, has filed a Report on Form 6-K with the United States Securities and Exchange Commission for February 2024, confirming its compliance with the shareholders' equity requirement for continued listing on the Nasdaq Capital Market. The company had previously reported shareholders' equity below the $2.5 million threshold as of October 31, 2023. However, Clearmind Medicine has since increased its shareholders' equity to approximately $7 million, following the exercise of warrants from its March and September 2023 public offerings and a registered direct offering and private placement in January 2024. The company believes it has regained compliance with the Nasdaq's listing requirements and understands that Nasdaq will monitor its ongoing compliance, with potential delisting if non-compliance is found in the next interim report.
外国私人发行人Clearmind Medicine Inc. 已向美国证券交易委员会提交了2024年2月的6-K表报告，确认其遵守了继续在纳斯达克资本市场上市的股东权益要求。该公司此前曾报告称，截至2023年10月31日，股东权益低于250万美元的门槛。但是，继行使2023年3月和9月的公开发行以及2024年1月的注册直接发行和私募股权证之后，Clearmind Medicine已将其股东权益增加到约700万美元。该公司认为已经恢复了对纳斯达克上市要求的遵守，并了解到纳斯达克将监督其持续合规情况，如果在下一份中期报告中发现违规行为，可能会将其退市。
外国私人发行人Clearmind Medicine Inc. 已向美国证券交易委员会提交了2024年2月的6-K表报告，确认其遵守了继续在纳斯达克资本市场上市的股东权益要求。该公司此前曾报告称，截至2023年10月31日，股东权益低于250万美元的门槛。但是，继行使2023年3月和9月的公开发行以及2024年1月的注册直接发行和私募股权证之后，Clearmind Medicine已将其股东权益增加到约700万美元。该公司认为已经恢复了对纳斯达克上市要求的遵守，并了解到纳斯达克将监督其持续合规情况，如果在下一份中期报告中发现违规行为，可能会将其退市。
有用
没用